Meropenem Qilu (Meropenem)

Meropenem is a broad‑spectrum carbapenem used for severe bacterial infections.

• Complicated intra‑abdominal infections: provides bactericidal activity against mixed aerobic and anaerobic pathogens.
• Complicated urinary tract infections: eradicates resistant Gram‑negative organisms.
• Hospital‑acquired pneumonia: treats multidrug‑resistant strains causing lower respiratory infection.
• Severe sepsis and septic shock: offers rapid bacterial clearance in critical care.
• Meningitis: penetrates the cerebrospinal fluid to eliminate causative bacteria.

• Meropenem binds to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial lysis. Its broad affinity for multiple PBPs gives activity against a wide range of Gram‑positive, Gram‑negative, and anaerobic organisms, including many resistant strains.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limited.
• Rash: erythematous skin eruption.
• Headache: transient discomfort.
• Elevated liver enzymes: mild transaminase increase.
• Injection site phlebitis: local irritation at IV site.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disease.
• Clostridioides difficile colitis: severe diarrhea due to gut flora disruption.
• Anaphylaxis: acute, potentially life‑threatening allergic reaction.
• Severe neutropenia: marked reduction in white blood cells.
• Renal toxicity: acute kidney injury in susceptible individuals.
• Hypersensitivity reactions: including Stevens‑Johnson syndrome.

Key safety considerations should be observed before and during therapy.

• Renal impairment: adjust dose based on creatinine clearance.
• Hypersensitivity: avoid in patients with known carbapenem allergy.
• Pregnancy: use only if benefit outweighs potential risk.
• Liver function: monitor transaminases during prolonged treatment.
• Concomitant valproic acid: increased risk of seizures; consider alternative.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug‑drug interactions require assessment.

Major Interactions (Avoid)

• Valproic acid: may lower seizure threshold when combined with meropenem.
• Other carbapenems: competitive inhibition may reduce efficacy.
• Probenecid: decreases renal excretion, increasing meropenem levels.

Moderate Interactions (Monitor Closely)

• Aminoglycosides: additive nephrotoxicity; monitor renal function.
• Loop diuretics: may enhance renal clearance, affecting exposure.
• Warfarin: possible INR fluctuations; check coagulation parameters.
• Oral contraceptives: reduced effectiveness; advise alternative contraception.
• NSAIDs: increased risk of renal impairment; observe kidney function.